TuHURA Biosciences (HURA) Total Liabilities (2011 - 2026)
TuHURA Biosciences (HURA) posted quarterly Total Liabilities of $6.5 million for Q1 2026, up 36.23% year-over-year from $4.8 million in Q1 2025, and up 1.47% quarter-over-quarter from $6.4 million in Q4 2025.
TuHURA Biosciences (HURA) Total Liabilities (2011 - 2026) Analysis & Trends
TuHURA Biosciences' Total Liabilities history runs 16 years deep, the most recent figure standing at $6.5 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 36.23% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (up 36.23% YoY), while the FY2025 annual figure was $6.4 million, up 19.51% from the prior year.
- Total Liabilities for Q1 2026 stood at $6.5 million, up from $6.4 million in the prior quarter.
- The five-year high for Total Liabilities was $15.2 million in Q2 2025, with the low at $1.5 million in Q1 2024.
- The 5-year median for Total Liabilities is $3.6 million (2022), against an average of $4.9 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities tumbled 48.41% in 2024, then soared 520.52% in 2025.
- TuHURA Biosciences' Total Liabilities stood at $3.3 million in 2022, then jumped by 78.38% to $5.9 million in 2023, then fell by 9.25% to $5.4 million in 2024, then rose by 19.51% to $6.4 million in 2025, then rose by 1.47% to $6.5 million in 2026.
- Business Quant data shows HURA's Total Liabilities at $6.5 million in Q1 2026, $6.4 million in Q4 2025, and $8.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | 13.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.51 Mn |
| Dec 31, 2025 | 6.42 Mn |
| Sep 30, 2025 | 8.92 Mn |
| Jun 30, 2025 | 15.17 Mn |
| Mar 31, 2025 | 4.78 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | 1.52 Mn |
| Dec 31, 2023 | 5.92 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 4.15 Mn |
| Mar 31, 2022 | 3.41 Mn |
| Dec 31, 2021 | 3.62 Mn |
| Sep 30, 2021 | 3.18 Mn |
| Jun 30, 2021 | 2.96 Mn |